Abstract
Nitroxyl (HNO), the one electron reduced form of nitric oxide (NO), shows a very distinct chemistry and biology from that of NO. Chemical profile is characterized by reactions with thiols and thiol proteins such as aldehyde dehydrogenase, glyceraldehyde 3-phosphate dehydrogenase, caspases among others. Biological profile of HNO includes cardioprotective actions especially in cases of heart failure. This short review focuses on the cytotoxic properties for HNO. Nitroxyl was found to be toxic to several cancer cell lines including lung and breast cancers. Critical thiols that control cancer cellular functions might be the target for HNO activity. The anti-tumor actions of HNO donating aspirin is also summarized.
Keywords: Nitroxyl, HNO, Anti-cancer, Nitric oxide, Angeli’s salt, IPA/NO-aspirin.
Graphical Abstract
Current Topics in Medicinal Chemistry
Title:Nitroxyl (HNO): A Possible Strategy for Fighting Cancer
Volume: 16 Issue: 22
Author(s): Mai E. Shoman and Omar M. Aly
Affiliation:
Keywords: Nitroxyl, HNO, Anti-cancer, Nitric oxide, Angeli’s salt, IPA/NO-aspirin.
Abstract: Nitroxyl (HNO), the one electron reduced form of nitric oxide (NO), shows a very distinct chemistry and biology from that of NO. Chemical profile is characterized by reactions with thiols and thiol proteins such as aldehyde dehydrogenase, glyceraldehyde 3-phosphate dehydrogenase, caspases among others. Biological profile of HNO includes cardioprotective actions especially in cases of heart failure. This short review focuses on the cytotoxic properties for HNO. Nitroxyl was found to be toxic to several cancer cell lines including lung and breast cancers. Critical thiols that control cancer cellular functions might be the target for HNO activity. The anti-tumor actions of HNO donating aspirin is also summarized.
Export Options
About this article
Cite this article as:
Shoman E. Mai and Aly M. Omar, Nitroxyl (HNO): A Possible Strategy for Fighting Cancer, Current Topics in Medicinal Chemistry 2016; 16 (22) . https://dx.doi.org/10.2174/1568026616666160212123006
DOI https://dx.doi.org/10.2174/1568026616666160212123006 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pharmacokinetics of Biotech Drugs: Peptides, Proteins and Monoclonal Antibodies
Current Drug Metabolism Imaging of Integrins as Biomarkers for Tumor Angiogenesis
Current Pharmaceutical Design Peptide Agonists and Antagonists with Potential Application in Neurological Disorders
Recent Patents on CNS Drug Discovery (Discontinued) Th17 and Treg Cells, Two New Lymphocyte Subpopulations with a Key Role in the Immune Response Against Infection
Infectious Disorders - Drug Targets Prothymosin Alpha: An Alarmin and More...
Current Medicinal Chemistry Signalling Pathways Activated by Ultraviolet Radiation: Role in Ocular and Cutaneous Health
Current Pharmaceutical Design Mouse ATP-Binding Cassette (ABC) Transporters Conferring Multi-Drug Resistance
Anti-Cancer Agents in Medicinal Chemistry Medicinal Chemistry of P2X Receptors: Agonists and Orthosteric Antagonists
Current Medicinal Chemistry Abnormal Choline Phospholipid Metabolism in Breast and Ovary Cancer:Molecular Bases for Noninvasive Imaging Approaches
Current Medical Imaging The cytotoxic effect of GW843682X on nasopharyngeal carcinoma
Anti-Cancer Agents in Medicinal Chemistry Fragment-Based Optimization of Small Molecule CXCL12 Inhibitors for Antagonizing the CXCL12/CXCR4 Interaction
Current Topics in Medicinal Chemistry MicroRNAs and the Response of Prostate Cancer to Anti-Cancer Drugs
Current Drug Targets The CXCR4/SDF-1 Chemokine Axis: A Potential Therapeutic Target for Bone Metastases?
Current Pharmaceutical Design Alterations in Glucose Metabolism in Alzheimer's Disease
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) The Anticancer Effect of Sanguinarine: A Review
Current Pharmaceutical Design Vascular Effects of Phytoestrogens and Alternative Menopausal Hormone Therapy in Cardiovascular Disease
Mini-Reviews in Medicinal Chemistry Q-TOF LC/MS-based Untargeted Metabolomics Approach to Evaluate the Effect of Folate-Conjugated Cyclodextrins on Triple-Negative Breast Cancer Cells
Current Pharmaceutical Analysis The Role of Antiangiogenetic Agents in the Treatment of Breast Cancer
Current Medicinal Chemistry Gonioprobe, an Innovative Gamma-probe to Guide Parathyroid Radioguided Surgery: First Clinical Experiences with Navigator and Lock-ontarget Functions
Current Radiopharmaceuticals Modulation of Gene Transcription by Natural Products - A Viable Anticancer Strategy
Current Pharmaceutical Design